When children are young, they love to drive you up the wall and seem to take particular pride in picking at one another. They put on their best-worst behaviour for you on the morning your eyeliner is crooked, you’ve only rinsed out half of the shampoo, and you’re running late. From the back seat of the car, there’s a debate on whether someone is being touched. A finger just a hair too close will warrant a, “Mom, he’s touching me!” And then the culprit, having learned how to avoid punishment, will say, “No, my finger is just really close.” Well, hello, lupus! I want to pull this car over and handle things, but this disease acts up at the worst possible times.
Right now, lupus has “my happy” and “my sad” in the back seat, and they are touching one another. They don’t like it. I don’t like it, but lupus is the kid who is taking some sort kind of weird pleasure in the attention it is getting. Lupus waits until I have a new symptom just barely under control to start annoying the other kid in the backseat.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs
